Literature DB >> 12663579

Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database.

David F Penson1, David M Latini, Deborah P Lubeck, Katrine L Wallace, James M Henning, Tom F Lue.   

Abstract

OBJECTIVE: Little is known regarding how diabetic men with erectile dysfunction (ED) differ from the general population of impotent men. The primary objective of this study was to compare disease-specific health-related quality of life (HRQOL) and severity of ED in impotent men with and without diabetes. RESEARCH DESIGN AND METHODS: Validated functional and HRQOL questionnaires (including the International Index of Erectile Function, the Sexual Self-Efficacy Scale, and the Psychological Impact of Erectile Dysfunction scales) were administered to patients in an ED disease registry. Men with ED and a history of diabetes (n = 20) were compared with men with ED and no history of diabetes (n = 90) at baseline and at the 12-month follow-up.
RESULTS: Diabetic impotent men reported worse erectile function and intercourse satisfaction at baseline, and ED had a greater impact on their emotional life. Diabetic men with ED had significantly different trends over time in the Erectile Function (P < 0.001), Intercourse Satisfaction (P < 0.013), Sexual Desire (P < 0.016), Overall Satisfaction (P < 0.023), and the Sexual Experience-Psychological Impact domains (P < 0.002). In addition, there was a trend toward a difference over time in the Emotional Life-Psychological Impact domain (P < 0.067).
CONCLUSIONS: Impotent men with diabetes present with worse ED than nondiabetic men with ED, resulting in worse disease-specific HRQOL in the diabetic men. Although diabetic patients initially respond well to ED treatment, responses do not appear to be durable over time. Therefore, clinicians must provide longer-term follow-up when treating ED in diabetic patients.

Entities:  

Mesh:

Year:  2003        PMID: 12663579     DOI: 10.2337/diacare.26.4.1093

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  49 in total

1.  Microarray analysis reveals novel gene expression changes associated with erectile dysfunction in diabetic rats.

Authors:  Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells
Journal:  Physiol Genomics       Date:  2005-08-23       Impact factor: 3.107

2.  Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials.

Authors:  V Fonseca; A Seftel; J Denne; P Fredlund
Journal:  Diabetologia       Date:  2004-11-25       Impact factor: 10.122

3.  Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

Authors:  Dean Patterson; Gordon T McInnes; John Webster; Malcolm M Mitchell; Thomas M Macdonald
Journal:  Br J Clin Pharmacol       Date:  2006-09       Impact factor: 4.335

4.  Depressive symptoms and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: the Dogo Study.

Authors:  S Furukawa; T Sakai; T Niiya; H Miyaoka; T Miyake; S Yamamoto; K Maruyama; T Ueda; H Senba; M Torisu; H Minami; M Onji; T Tanigawa; B Matsuura; Y Hiasa; Y Miyake
Journal:  Int J Impot Res       Date:  2016-11-17       Impact factor: 2.896

5.  Molecular targets for diabetes mellitus-associated erectile dysfunction.

Authors:  Elizabeth Yohannes; Jinsook Chang; Moses T Tar; Kelvin P Davies; Mark R Chance
Journal:  Mol Cell Proteomics       Date:  2009-12-10       Impact factor: 5.911

6.  Lack of awareness of erectile dysfunction in many men with risk factors for erectile dysfunction.

Authors:  Ridwan Shabsigh; Joel Kaufman; Michelle Magee; Dana Creanga; David Russell; Meeta Budhwani
Journal:  BMC Urol       Date:  2010-11-05       Impact factor: 2.264

7.  ROS activates JNK-mediated autophagy to counteract apoptosis in mouse mesenchymal stem cells in vitro.

Authors:  Guan-yu Liu; Xiao-xue Jiang; Xin Zhu; Wei-yang He; You-lin Kuang; Ke Ren; Yong Lin; Xin Gou
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

8.  Erectile dysfunction in young men with type 1 diabetes.

Authors:  M I Maiorino; G Bellastella; E Della Volpe; O Casciano; L Scappaticcio; P Cirillo; D Giugliano; K Esposito
Journal:  Int J Impot Res       Date:  2016-09-22       Impact factor: 2.896

9.  The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients.

Authors:  G Corona; C B Giorda; D Cucinotta; P Guida; E Nada
Journal:  J Endocrinol Invest       Date:  2013-05-20       Impact factor: 4.256

Review 10.  Vardenafil for the treatment of erectile dysfunction: an overview of the clinical evidence.

Authors:  Antonio Martín Morales; Vincenzo Mirone; John Dean; Pierre Costa
Journal:  Clin Interv Aging       Date:  2009-12-29       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.